Skip to main content

Advertisement

Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro

Fig. 6

Baricitinib blocks reservoir establishment, maintenance, and expansion in primary human T cells and macrophages. Baricitinib demonstrates nanomolar inhibition of HIV replication in primary human macrophages and T cells, block of HIV-induced activation in macrophages, and HIV reactivation in T cells and macrophages (a). The concentrations that confer these anti-HIV effects are within the steady-state concentration range for approved doses of baricitinib in humans (b). Individual dose responses for data reported appear in Additional file 1: Figure S1

Back to article page